Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Clicks: 1
ID: 295322
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #233 of 310 articles by views in european heart journal
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 310 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7–29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.
| Reference Key |
openalex_W2134159541
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Erik S.G. Stroes, Paul M. Thompson, Alberto Corsini, Georgirene D. Vladutiu, Frederick J. Raal, Kausik K. Ray, Michael Roden, Evan A. Stein, Lâle Tokgözoğlu, Børge G. Nordestgaard, Éric Bruckert, Guy De Backer, Ronald M. Krauss, Ulrich Laufs, Raúl D. Santos, Robert A. Hegele, G. Kees Hovingh, Lawrence A. Leiter, François Mach, Winfried März, Connie B. Newman, Olov Wiklund, Terry A. Jacobson, Alberico L. Catapano, M. John Chapman, Henry N. Ginsberg, Erik S.G. Stroes, Paul M. Thompson, Alberto Corsini, Georgirene D. Vladutiu, Frederick J. Raal, Kausik K. Ray, Michael Roden, Evan A. Stein, Lâle Tokgözoğlu, Børge G. Nordestgaard, Éric Bruckert, Ronald M. Krauss, Ulrich Laufs, Raúl D. Santos, Winfried März, Connie B. Newman, M. John Chapman, Henry N. Ginsberg, M. John Chapman, Henry N. Ginsberg, Guy De Backer, Alberico L. Catapano, Robert A. Hegele, G. Kees Hovingh, Terry A. Jacobson, Lawrence A. Leiter, François Mach, Olov Wiklund |
| Journal | european heart journal |
| Year | 2015 |
| DOI |
10.1093/eurheartj/ehv043
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.